Harbin Medisan Pharmaceutical Co., Ltd. (SHE:002900)
China flag China · Delayed Price · Currency is CNY
12.97
-0.01 (-0.08%)
Sep 30, 2026, 3:04 PM CST

SHE:002900 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Operating Revenue
720.52706.971,0711,1531,008910.39
Other Revenue
84.5782.4561.6434.0920.2735.41
805.09789.421,1321,1871,028945.8
Revenue Growth
-21.24%-30.29%-4.58%15.40%8.73%-29.36%
Cost of Revenue
541.38530.78553.88475.55360.34312.86
Gross Profit
263.71258.65578.6711.23668.08632.94
Selling, General & Admin
454.63487.94432.05598.15594.6667.1
Research & Development
83.6393.16105.22112.8189.2799.92
Other Operating Expenses
15.758.457.3911.115.5314.14
Operating Expenses
552.95586.94545.88719.2699.98782.97
Operating Income
-289.24-328.2932.72-7.97-31.91-150.03
Interest Expense
-27.37-26.47-31.32-22.89-22.62-13.8
Interest & Investment Income
26.5829.1555.4570.5474.24609.35
Currency Exchange Gain (Loss)
-0.210.250.510.141.57-0.02
Other Non Operating Income (Expenses)
2.620.693.97-0.26-1.06-0.37
EBT Excluding Unusual Items
-287.61-324.6761.3439.5620.22445.12
Impairment of Goodwill
-0.5-0.5----
Gain (Loss) on Sale of Investments
-9.32-11.31-14.6413.3713.87-5.13
Gain (Loss) on Sale of Assets
-0.97-0.520.19-2.61-13.31-1.92
Asset Writedown
-31-31.09-0-0-2.91-0.68
Legal Settlements
0.190.19----
Other Unusual Items
31.5514.8713.1131.0622.215.45
Pretax Income
-297.67-353.0360.0181.3740.07452.86
Income Tax Expense
-5.05-11.475.0311.313.57103.18
Earnings From Continuing Operations
-292.62-341.5754.9870.0826.5349.68
Minority Interest in Earnings
1.191.943.73.583.711.27
Net Income
-291.43-339.6358.6873.6630.21350.95
Net Income to Common
-291.43-339.6358.6873.6630.21350.95
Net Income Growth
---20.35%143.86%-91.39%1096.77%
Shares Outstanding (Basic)
316317309307302311
Shares Outstanding (Diluted)
316317309307302311
Shares Change
3.96%2.78%0.61%1.61%-2.74%-4.68%
EPS (Basic)
-0.92-1.070.190.240.101.13
EPS (Diluted)
-0.92-1.070.190.240.101.13
EPS Growth
---20.83%140.00%-91.15%1155.56%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
-180.64-283.98-315.52-263.8955.42-86.48
Free Cash Flow Per Share
-0.57-0.90-1.02-0.860.18-0.28
Dividend Per Share
--0.2000.2000.1000.320
Dividend Growth
--0%100.00%-68.75%300.00%
Gross Margin
32.76%32.76%51.09%59.93%64.96%66.92%
Operating Margin
-35.93%-41.59%2.89%-0.67%-3.10%-15.86%
Profit Margin
-36.20%-43.02%5.18%6.21%2.94%37.11%
Free Cash Flow Margin
-22.44%-35.97%-27.86%-22.23%5.39%-9.14%
EBITDA
-152.3-195.57133.6390.4365.02-60.22
EBITDA Margin
-18.92%-24.77%11.80%7.62%6.32%-6.37%
D&A For EBITDA
136.93132.71100.9198.4196.9289.81
EBIT
-289.24-328.2932.72-7.97-31.91-150.03
EBIT Margin
-35.93%-41.59%2.89%-0.67%-3.10%-15.86%
Effective Tax Rate
--8.38%13.88%33.87%22.78%
Revenue as Reported
805.09789.421,1321,1871,028945.8
Advertising Expenses
-23.2716.6251.4643.2431.69